FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Cytokinetics (NASDAQ: CYTK) after the company, in conjunction ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE